<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00548405</url>
  </required_header>
  <id_info>
    <org_study_id>CAMMS32400507</org_study_id>
    <secondary_id>2007-001162-32</secondary_id>
    <secondary_id>CAMMS324,</secondary_id>
    <secondary_id>ISRCTN70702834</secondary_id>
    <secondary_id>ACTRN12608000426381</secondary_id>
    <secondary_id>NTR1469</secondary_id>
    <secondary_id>CARE-MS II</secondary_id>
    <nct_id>NCT00548405</nct_id>
  </id_info>
  <brief_title>Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two</brief_title>
  <acronym>CARE-MS II</acronym>
  <official_title>A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to establish the efficacy and safety of two different doses of
      alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in
      comparison with subcutaneous interferon beta-1a (Rebif®). The study enrolled participants who
      had received an adequate trial of disease-modifying therapies but experienced at least 1
      relapse during prior treatment, and who met a minimum severity of disease as measured by
      magnetic resonance imaging (MRI). Participants had monthly laboratory tests and comprehensive
      testing every 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Every participant received active treatment; there was no placebo. After Amendment 2, the 24
      mg alemtuzumab dose was closed to enrollment so newly enrolled participants were randomly
      assigned to treatment with either 12 mg alemtuzumab or interferon beta-1a in a 2:1 ratio
      (that is, 2 given 12 mg alemtuzumab for every 1 given interferon beta-1a). Alemtuzumab was
      administered in two annual courses, once at the beginning of the study and again 1 year
      later. Interferon beta-1a was self-injected 3 times per week for 2 years. All participants
      were required to return to their study site every 3 months for neurologic assessment. In
      addition, safety-related laboratory tests were performed at least monthly. Participation in
      this study ended 2 years after the start of treatment for each participant. Additionally,
      participants who received alemtuzumab might be followed in the CAMMS03409 Extension Study
      (NCT00930553) for safety and efficacy assessments. Participants who received interferon
      beta-1a and completed 2 years on study might be eligible to receive alemtuzumab in the
      Extension Study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Accumulation of Disability (SAD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with a Baseline score of 1.0 or more; and the increase persisted for at least the next 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Percentage of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated through negative binomial regression with robust variance estimation and covariate adjustment for geographic region using observed number of relapses as dependent variable, the log total amount of follow-up from date of first study treatment for each participant as an offset variable, and treatment group and geographic region as model covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Relapse Free at Year 2</measure>
    <time_frame>Year 2</time_frame>
    <description>Participants were considered relapse free at Year 2 if they did not experience a relapse from the date of first study treatment to study completion at 24 months. Percentage of participants who were relapse free at Year 2, estimated using the KM method, was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Change was calculated by subtracting Baseline value from value at Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>MSFC is a multidimensional measure consisting of quantitative tests of ambulation (Timed 25-Foot Walk), manual dexterity (9-Hole Peg Test; 9HPT), and cognitive function (Paced Auditory Serial Addition Test; PASAT). The MSFC score was calculated as the mean of the Z-scores of the 3 components. A Z-score was calculated by subtracting the mean of the reference population from the test result, then dividing by the standard deviation of the reference population. Higher Z-scores reflected better neurological function and a positive change from Baseline indicates improvement. An increase in score indicated an improvement (Z-score range: -3 to +3). Acquisition of disability was measured by change from Baseline in MSFC score at Year 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2</measure>
    <time_frame>Baseline, Year 2</time_frame>
    <description>Percent change in MS lesion volume as measured by MRI-T2 scan was calculated from MRI-T2-weighted scans as the following: (lesion volume at 2 years - lesion volume at Baseline)*100/ (lesion volume at Baseline).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">840</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alemtuzumab 24 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon Beta-1a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab 12 mg</intervention_name>
    <description>Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
    <arm_group_label>Alemtuzumab 12 mg</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Alemtuzumab 24 mg</intervention_name>
    <description>Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.</description>
    <arm_group_label>Alemtuzumab 24 mg</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
    <arm_group_label>Interferon Beta-1a</arm_group_label>
    <other_name>Rebif®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form (ICF)

          -  Age 18 to 55 years (inclusive) as of the date the ICF was signed

          -  Diagnosis of MS per update of McDonald criteria

          -  Onset of MS symptoms (as determined by a neurologist; could be retrospectively) within
             10 years of the date the ICF was signed

          -  Expanded Disability Status Scale (EDSS) score 0.0 to 5.0 (inclusive) at Screening

          -  Greater than or equal to (&gt;=) 2 MS attacks (first episode or relapse) occurring in the
             24 months prior to the date the ICF was signed, with &gt;=1 attack in the 12 months prior
             to the date the ICF was signed, with objective neurological signs confirmed by a
             physician, nurse practitioner, or other Genzyme-approved health-care provider and the
             objective signs could be identified retrospectively

          -  &gt;=1 MS relapse during treatment with a beta interferon therapy or glatiramer acetate
             after having been on that therapy for &gt;=6 months within 10 years of the date the ICF
             was signed

          -  MRI scan demonstrating white matter lesions attributable to MS and meeting at least 1
             of the following criteria, as determined by the neurologist or a radiologist: &gt;=9 time
             constant 2 (T2) lesions at least 3 millimeter (mm) in any axis; a gadolinium- (Gd-)
             enhancing lesion at least 3 mm in any axis plus &gt;=1 brain T2 lesions; and a spinal
             cord lesion consistent with MS plus &gt;=1 brain T2 lesion

        Exclusion Criteria:

          -  Received prior therapy with alemtuzumab

          -  Current participation in another clinical study or previous participation in CAMMS323
             (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, CARE-MS I)

          -  Treatment with natalizumab, methotrexate, azathioprine, or cyclosporine in the past 6
             months. Participants who received one of these medications more than 6 months before
             the date the ICF was signed were eligible for study entry if approval was granted by
             Genzyme

          -  Any progressive form of MS

          -  History of malignancy (except basal skin cell carcinoma)

          -  CD4 +, CD8 +, CD19 + (that is, absolute CD3 + CD4 + , CD3 + CD8 + , or CD19 + /mm 3 )
             count, absolute neutrophil count less than (&lt;) lower limit of normal (LLN) at
             screening; if abnormal cell count(s) returned to within normal limits (WNL),
             eligibility could be reassessed

          -  Known bleeding disorder (for example, dysfibrinogenemia, factor IX deficiency,
             hemophilia, Von Willebrand's disease, disseminated intravascular coagulation,
             fibrinogen deficiency, or clotting factor deficiency)

          -  Significant autoimmune disease including but not limited to immune cytopenias,
             rheumatoid arthritis, systemic lupus erythematosus, other connective tissue disorders,
             vasculitis, inflammatory bowel disease, severe psoriasis

          -  Presence of anti-thyroid stimulating hormone (TSH) receptor (TSHR) antibodies (that
             is, above the LLN)

          -  Active infection or at high risk for infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Neurology Associates, P.C.</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute, St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona, Department of Neurology</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists, PLLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Physicians Medical Group/Sutter East Bay Medical Foundation</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Keck School of Medicine, University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Therapeutics Inc.</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Therapeutics, Inc</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital, Anschutz Outpatient Pavilioin</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Consultants</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Research</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Neuroscience Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.A.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Associates</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Negroski, Stein, Sutherland and Hanes Neurology</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axiom Clinical Research of Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Department of Neurology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University, Department of Neurology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Center, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho Falls Multiple Sclerosis Center, PLLC</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center, Department of Neurology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology, Ltd</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine, Department of Neurology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology P.C.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Health Physicians</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruan Neurology Clinic and Research Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center, Department of Neurology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MidAmerica Neuroscience Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Neurology, PSC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Partners Multiple Sclerosis Center/Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Neurology Associates, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Department of Neurology</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University, School of Medicine, Department of Neurology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Medical Group, Neurology (Previously known as Michigan Medical P.C., Neurology)</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Neurology Associates, P.C.</name>
      <address>
        <city>St. Clair Shores</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Neurology</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Kansas City, Inc.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Neurobehavioral Specialists</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Neurosciences / Renown regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center at Holy Name Hospital</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico, Health Sciences Center, MS Specialty Clinic</name>
      <address>
        <city>Alburquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Empire Neurology, PC</name>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital, Clinical Trials Center</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C.</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University, Department of Neurology</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina-Chapel Hill, Department of Neurology</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Science, Department of Neurology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation, Mellen Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oak Clinic for Multiple Sclerosis</name>
      <address>
        <city>Uniontown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital, Neuroscience and Pain Research</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Clinical Associates</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Kaufmann Medical Building</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Neurology Foundation, Inc.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic, P.C.</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Institute</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Alliance of NY, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Neurology PC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Multiple Sclerosis Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center for Multiple Sclerosis</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integra Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of Greater Washington, P.C.</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinical Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIABAID</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Wesley Research Institute</name>
      <address>
        <city>Auchenflower</city>
        <state>Queensland</state>
        <zip>4066</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Griffith School of Medicine, Gold Coast Campus, Griffith University</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Cognitive Research Unit/Clinical Trials, The Queen Elizabeth Hospital, Neurology Department</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, MS Education &amp; Research, Department of Clinical Neurosciences</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital, Department of Neurology</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital, Neurosciences Department</name>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Neurology</name>
      <address>
        <city>Kogarah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital, Neurology Department</name>
      <address>
        <city>Liverpool</city>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien, Universitätsklinikum für Neurologie</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc, Neurology</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ourthe Amblève, Neurology</name>
      <address>
        <city>Esneux</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven, Campus Gasthuisberg, Neurology</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital da Restauracao</name>
      <address>
        <city>Recife</city>
        <state>PE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas PUC-RS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas USP</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBC Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sclerosis Clinic, Connell 7, Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre- University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital, General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Sante et de Services Sociaux de Gatineau-Hull Hospital</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Neuro rive-sud, Recherche sepmus inc</name>
      <address>
        <city>Greenfield park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Rijeka, Clinic for Neurology</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Varazdin, Department of neurology</name>
      <address>
        <city>Varazdin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot; Sveti Duh&quot;, Department of neurology</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center, Department of Neurology</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anne's University Hospital Brno</name>
      <address>
        <city>Pekarska</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology 1st Faculty of Medicine and General Teaching Hospital, MS Center</name>
      <address>
        <city>Praha 2</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni a.s. - Hospital Teplice</name>
      <address>
        <city>Teplice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Århus Universitetshospital, Scleroseklinikken, Århus Sygehus</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scleroseklinikken, Rigshospitalet</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand, Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital General, Service de Neurologie</name>
      <address>
        <city>Dijon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Roger Salengro</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière, Service de Neurologie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sevice de Neurologie</name>
      <address>
        <city>Rennes Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil, Departement de Neurologie</name>
      <address>
        <city>Strasbourg Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hohe Warte, Betriebsstätte der Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Judisches Krankenhaus Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Fachzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiple Sklerose Zentrum am, Zentrum für klinische Neurowissenschaften, Neurologische Uniklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinic Barmbek</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochshule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oberhavelkliniken Hennigsdorf</name>
      <address>
        <city>Hennigsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt, Neurologische Klinik</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar, Klinik für Neurologie</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fur Neurologie der Universitat Rockstock</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Hubertusburg</name>
      <address>
        <city>Wermsdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center Ein Karem</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center, Department of Neurology</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Centre</name>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Binaghi - Centro Sclerosi Multipla</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Antonio Abate di Gallarate</name>
      <address>
        <city>Gallarate</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università di Genova Dipartimento di Neuroscienze Oftalmologia e Genetica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Brescia c/o Ospedale Richiedei, Centro di riferimento per la Sclerosi Multiple</name>
      <address>
        <city>Montichiari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luigi di Orbassano</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea Neurologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Medica Sur CIF-BIOTEC</name>
      <address>
        <city>Delegacion</city>
        <state>Tlalpan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación en Salud de Chihuahua, S.C.</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Angeles del Pedregal; Camino a Santa Teresa</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum, Department of Neurology</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Healthcare Facility, Norbert Barlicki University Hospital No. 1 of the Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Public Teaching Hospital No. 4 in Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heliodor Swiecicki Teaching Hospital of the Poznan, University of Medical Sciences</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Complex &quot;Your Health&quot; Ltd</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences, &quot;Neurology Scientific Center under RAMS&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Medical Institution City Clinical Hospital #11, Moscow City Center for Multiple Sclerosis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State Public Medical Institution, City Clinical Hospital #11</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Treatment and Prevention Institution, &quot;City Hospital #33&quot;</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Institution: Siberian District Medical Center</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution, &quot;Samara Regional Clinical Hospital n.a. M.I. Kalinin&quot;</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Sciences, &quot;Institute of the Human Brain n.a. N.P. Bekhtereva within the Russian Academy of Sciences&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Pavlov State Medical University, Department of Neurology and Neurosurgery with a Clinic</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Medical Institution, &quot;City Multispecialty Hospital #2&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Medical Institution, &quot;Nikolayevskaya Hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Neurology, Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre Vojvodina Institute of Neurology</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurología Hospital Vall d'Hebron Paseo de Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurología Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurología Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Neurología Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Neurologkliniken</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norrlands Universitets sjukhus</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Psychiatry and Narcology under the Academy of Medical Sciences of Ukraine</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Municipal Clinical Hospital #4, Department of Demyelinating Diseases of the Nervous System</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danylo Halytsky Lviv National Medical University, Department of Neurology</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department Of Neurosciences, Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Neuroscience &amp; Trauma, Blizard Institute of Cell and Molecular Science Barts and The London School of Medicine and Dentistry</name>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frenchay Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust, Clinical Trials Unit</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology Glossop Road, Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf</url>
    <description>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf</description>
  </link>
  <reference>
    <citation>Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.</citation>
    <PMID>23122650</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2007</study_first_submitted>
  <study_first_submitted_qc>October 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2007</study_first_posted>
  <results_first_submitted>November 17, 2014</results_first_submitted>
  <results_first_submitted_qc>January 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2015</results_first_posted>
  <disposition_first_submitted>November 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 4, 2012</disposition_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened at 192 investigational sites between October 10, 2007 and September 15, 2011.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Interferon Beta-1a</title>
          <description>Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
        </group>
        <group group_id="P2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
        </group>
        <group group_id="P3">
          <title>Alemtuzumab 24mg</title>
          <description>Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="231">Randomized.</participants>
                <participants group_id="P2" count="436">Randomized.</participants>
                <participants group_id="P3" count="173">Randomized.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="202">All randomized participants who received at least 1 dose of study drug as per initial randomization.</participants>
                <participants group_id="P2" count="426">All randomized participants who received at least 1 dose of study drug as per initial randomization.</participants>
                <participants group_id="P3" count="170">All randomized participants who received at least 1 dose of study drug as per initial randomization.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="416"/>
                <participants group_id="P3" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) population included all randomized participants who received at least 1 dose of study drug as per initial randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Interferon Beta-1a</title>
          <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
        </group>
        <group group_id="B2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion over 4 hours on 3 consecutive days at Month 12.</description>
        </group>
        <group group_id="B3">
          <title>Alemtuzumab 24mg</title>
          <description>Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion over 4 hours on 3 consecutive days at Month 12.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="426"/>
            <count group_id="B3" value="170"/>
            <count group_id="B4" value="798"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="8.77"/>
                    <measurement group_id="B2" value="34.8" spread="8.36"/>
                    <measurement group_id="B3" value="35.1" spread="8.40"/>
                    <measurement group_id="B4" value="35.1" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="281"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="532"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time Since First Relapse</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" lower_limit="0.4" upper_limit="10.1"/>
                    <measurement group_id="B2" value="3.8" lower_limit="0.2" upper_limit="14.4"/>
                    <measurement group_id="B3" value="3.7" lower_limit="0.2" upper_limit="16.9"/>
                    <measurement group_id="B4" value="3.8" lower_limit="0.2" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Relapse Episodes in the Preceding 2 Years</title>
          <description>Number of participants with 1, 2 or greater than or equal to 3 relapses are reported.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 3 Relapses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Expanded Disability Status Scale (EDSS) Score</title>
          <description>EDSS is an ordinal scale in half-point increments that quantifies disability in participants with multiple sclerosis (MS). It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="1.21"/>
                    <measurement group_id="B2" value="2.7" spread="1.26"/>
                    <measurement group_id="B3" value="2.7" spread="1.17"/>
                    <measurement group_id="B4" value="2.7" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Accumulation of Disability (SAD)</title>
        <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with a Baseline score of 1.0 or more; and the increase persisted for at least the next 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Percentage of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>FAS population included all randomized participants who received at least 1 dose of study drug as per initial randomization. Analysis was not performed for Alemtuzumab 24 mg as recruitment to this arm was closed early to reduce overall sample size, duration of enrollment period, overall duration of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Accumulation of Disability (SAD)</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with MS. It assesses 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score: 0 (normal neurological examination) to 10 (death due to MS). As measured by EDSS score, SAD was defined as increase of at least 1.5 points for participants with Baseline score of 0 and increase of at least 1.0 point for participants with a Baseline score of 1.0 or more; and the increase persisted for at least the next 2 scheduled assessments, that is, 6 consecutive months. The onset date of SAD was date of first EDSS assessment that began 6 month consecutive period of SAD. Participants who did not reach SAD endpoint were censored at their last visit. Percentage of participants with SAD, estimated by Kaplan-Meier (KM) method, was reported.</description>
          <population>FAS population included all randomized participants who received at least 1 dose of study drug as per initial randomization. Analysis was not performed for Alemtuzumab 24 mg as recruitment to this arm was closed early to reduce overall sample size, duration of enrollment period, overall duration of study.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.13" lower_limit="15.95" upper_limit="27.68"/>
                    <measurement group_id="O2" value="12.71" lower_limit="9.89" upper_limit="16.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox proportional hazards (PH) regression model with robust variance estimation using treatment group and geographic region as covariate was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0084</p_value>
            <p_value_desc>Hochberg method was used to adjust for the two co-primary outcomes.</p_value_desc>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate</title>
        <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated through negative binomial regression with robust variance estimation and covariate adjustment for geographic region using observed number of relapses as dependent variable, the log total amount of follow-up from date of first study treatment for each participant as an offset variable, and treatment group and geographic region as model covariates.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>FAS population. Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate</title>
          <description>Relapse was defined as new neurological symptoms or worsening of previous neurological symptoms with an objective change on neurological examination, attributable to multiple sclerosis that lasted for at least 48 hours, that were present at normal body temperature, and that were preceded by at least 30 days of clinical stability. Annualized relapse rate was estimated through negative binomial regression with robust variance estimation and covariate adjustment for geographic region using observed number of relapses as dependent variable, the log total amount of follow-up from date of first study treatment for each participant as an offset variable, and treatment group and geographic region as model covariates.</description>
          <population>FAS population. Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
          <units>relapses per participant per year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.41" upper_limit="0.66"/>
                    <measurement group_id="O2" value="0.26" lower_limit="0.21" upper_limit="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Proportional means regression model with robust variance estimation and covariate adjustment for geographic region was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hochberg method was used to adjust for the two co-primary outcomes.</p_value_desc>
            <method>Proportional means regression</method>
            <param_type>Rate ratio</param_type>
            <param_value>0.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Relapse Free at Year 2</title>
        <description>Participants were considered relapse free at Year 2 if they did not experience a relapse from the date of first study treatment to study completion at 24 months. Percentage of participants who were relapse free at Year 2, estimated using the KM method, was reported.</description>
        <time_frame>Year 2</time_frame>
        <population>FAS population. Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Relapse Free at Year 2</title>
          <description>Participants were considered relapse free at Year 2 if they did not experience a relapse from the date of first study treatment to study completion at 24 months. Percentage of participants who were relapse free at Year 2, estimated using the KM method, was reported.</description>
          <population>FAS population. Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="426"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.70" lower_limit="39.53" upper_limit="53.54"/>
                    <measurement group_id="O2" value="65.38" lower_limit="60.65" upper_limit="69.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Cox PH regression model with robust variance estimation and covariate adjustment for geographic region was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazards Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2</title>
        <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Change was calculated by subtracting Baseline value from value at Year 2.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>FAS population. Here, number of participants analyzed was subset of FAS who had EDSS assessment at both Baseline and end-of-study (Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Expanded Disability Status Scale (EDSS) Score at Year 2</title>
          <description>EDSS is an ordinal scale in half-point increments that qualifies disability in participants with multiple sclerosis (MS). It assesses the 7 functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel/bladder and cerebral) as well as ambulation. EDSS total score ranges from 0 (normal neurological examination) to 10 (death due to MS). Change was calculated by subtracting Baseline value from value at Year 2.</description>
          <population>FAS population. Here, number of participants analyzed was subset of FAS who had EDSS assessment at both Baseline and end-of-study (Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="413"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="1.167"/>
                    <measurement group_id="O2" value="-0.20" spread="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis was performed using Wei-Lachin method for non-parametric analysis of repeated measures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wei-Lachin</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2</title>
        <description>MSFC is a multidimensional measure consisting of quantitative tests of ambulation (Timed 25-Foot Walk), manual dexterity (9-Hole Peg Test; 9HPT), and cognitive function (Paced Auditory Serial Addition Test; PASAT). The MSFC score was calculated as the mean of the Z-scores of the 3 components. A Z-score was calculated by subtracting the mean of the reference population from the test result, then dividing by the standard deviation of the reference population. Higher Z-scores reflected better neurological function and a positive change from Baseline indicates improvement. An increase in score indicated an improvement (Z-score range: -3 to +3). Acquisition of disability was measured by change from Baseline in MSFC score at Year 2.</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>FAS population. Here, number of participants analyzed signifies subset of FAS who had MSFC score assessment at Baseline; 'n' signifies participants who had MSFC score assessment at Baseline (for Baseline) and at both Baseline and Year 2 (for change at Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Multiple Sclerosis Functional Composite (MSFC) Score at Year 2</title>
          <description>MSFC is a multidimensional measure consisting of quantitative tests of ambulation (Timed 25-Foot Walk), manual dexterity (9-Hole Peg Test; 9HPT), and cognitive function (Paced Auditory Serial Addition Test; PASAT). The MSFC score was calculated as the mean of the Z-scores of the 3 components. A Z-score was calculated by subtracting the mean of the reference population from the test result, then dividing by the standard deviation of the reference population. Higher Z-scores reflected better neurological function and a positive change from Baseline indicates improvement. An increase in score indicated an improvement (Z-score range: -3 to +3). Acquisition of disability was measured by change from Baseline in MSFC score at Year 2.</description>
          <population>FAS population. Here, number of participants analyzed signifies subset of FAS who had MSFC score assessment at Baseline; 'n' signifies participants who had MSFC score assessment at Baseline (for Baseline) and at both Baseline and Year 2 (for change at Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="423"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=198, 423)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.791"/>
                    <measurement group_id="O2" value="0.02" spread="0.689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Year 2 (n=169, 399)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.449"/>
                    <measurement group_id="O2" value="0.09" spread="0.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change at Year 2: the analysis was performed using Wei-Lachin method for non-parametric analysis of repeated measures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Wei-Lachin</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2</title>
        <description>Percent change in MS lesion volume as measured by MRI-T2 scan was calculated from MRI-T2-weighted scans as the following: (lesion volume at 2 years - lesion volume at Baseline)*100/ (lesion volume at Baseline).</description>
        <time_frame>Baseline, Year 2</time_frame>
        <population>FAS population. Here, number of participants analyzed was subset of FAS who had assessment for T2 volume at both Baseline and end-of-study (Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon Beta-1a</title>
            <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
          </group>
          <group group_id="O2">
            <title>Alemtuzumab 12 mg</title>
            <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Magnetic Resonance Imaging Time Constant 2 (MRI-T2) Hyperintense Lesion Volume at Year 2</title>
          <description>Percent change in MS lesion volume as measured by MRI-T2 scan was calculated from MRI-T2-weighted scans as the following: (lesion volume at 2 years - lesion volume at Baseline)*100/ (lesion volume at Baseline).</description>
          <population>FAS population. Here, number of participants analyzed was subset of FAS who had assessment for T2 volume at both Baseline and end-of-study (Year 2). Analysis was not performed for Alemtuzumab 24 mg as described in outcome measure 1.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="26.48"/>
                    <measurement group_id="O2" value="-1.12" spread="24.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ranked ANCOVA models with covariate adjustment for geographic region and Baseline T2 lesion volume was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1371</p_value>
            <method>Ranked ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose of study drug up to 2 years</time_frame>
      <desc>If a participant experienced a serious and a non-serious event with same term, individual was included in numerator of both adverse event tables. Safety population: all participants who received any amount of study drug (as treated). In Alemtuzumab 24 mg arm 9 participants received Alemtuzumab 12 mg, hence were included in Alemtuzumab 12 mg arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Interferon Beta-1a</title>
          <description>Interferon Beta-1a 44 mcg subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.</description>
        </group>
        <group group_id="E2">
          <title>Alemtuzumab 12 mg</title>
          <description>Alemtuzumab 12 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.</description>
        </group>
        <group group_id="E3">
          <title>Alemtuzumab 24 mg</title>
          <description>Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.</description>
        </group>
        <group group_id="E4">
          <title>Alemtuzumab (Pooled)</title>
          <description>Included all participants who received alemtuzumab 12 mg or 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg or 24 mg per day IV infusion on 3 consecutive days at Month 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Autoimmune thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Retinal pigment epitheliopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pasteurella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Vulval cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Automatic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oropharyngeal blistering</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Female sterilisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="427" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="586" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="156" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="141" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="180" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="104" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="129" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>CD8 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>T-lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="74" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="331" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="170" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="101" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="288" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="596"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="116" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="435"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="161"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="596"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can publish after sponsor published, after a defined period of time after study completion, and/or with written Sponsor approval. Generally PI gives sponsor a draft 60 days before publication. Sponsor can ask that confidential information can be removed, and can further defer publication upon notifying PI that it will file a patent application on inventions contained in the draft.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Efficacy analysis was not performed for Alemtuzumab 24 mg as recruitment to this arm was closed early to reduce overall sample size, duration of enrollment period, overall duration of study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi</organization>
      <email>Contact-us@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

